NASDAQ:EDIT - Editas Medicine Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Editas Medicine Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.35 -0.62 (-2.14 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$27.90Now: $28.35▼$29.3550-Day Range$28.35MA: $30.67▼$32.7852-Week Range$19.00Now: $28.35▼$34.37Volume703,783 shsAverage Volume686,519 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/ABeta2.63 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT Previous Symbol CUSIPN/A CIK1650664 Webhttp://www.editasmedicine.com/ Phone617-401-9000Debt Debt-to-Equity Ratio0.06 Current Ratio5.08 Quick Ratio5.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.94 million Price / Sales45.53 Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book5.74Profitability EPS (Most Recent Fiscal Year)($2.33) Net Income$-109,950,000.00 Net Margins-842.47% Return on Equity-56.53% Return on Assets-31.70%Miscellaneous Employees133 Outstanding Shares51,300,000Market Cap$1.45 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive EDIT News and Ratings via Email Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EDIT Rates by TradingView Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." How were Editas Medicine's earnings last quarter? Editas Medicine Inc (NASDAQ:EDIT) issued its earnings results on Tuesday, November, 12th. The company reported ($0.66) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.73) by $0.07. The company had revenue of $3.90 million for the quarter, compared to the consensus estimate of $4.72 million. Editas Medicine had a negative net margin of 842.47% and a negative return on equity of 56.53%. The firm's revenue for the quarter was down 73.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.32) EPS. View Editas Medicine's Earnings History. When is Editas Medicine's next earnings date? Editas Medicine is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Editas Medicine. What price target have analysts set for EDIT? 5 analysts have issued 12 month price targets for Editas Medicine's shares. Their forecasts range from $29.00 to $55.00. On average, they expect Editas Medicine's stock price to reach $38.00 in the next year. This suggests a possible upside of 34.0% from the stock's current price. View Analyst Price Targets for Editas Medicine. What is the consensus analysts' recommendation for Editas Medicine? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine. What are Wall Street analysts saying about Editas Medicine stock? Here are some recent quotes from research analysts about Editas Medicine stock: 1. According to Zacks Investment Research, "Editas' lead candidate EDIT-101, which uses CRISPR gene editing to treat LCA10, a genetic illness that causes blindness, is being developed in partnership with Allergan. The disease has a significant unmet need as no therapies are presently approved. A phase I/II dose escalation study on EDIT-101 initiated patient enrolment in July 2019. Editas has some high-profile collaborations with big pharma companies for its CRISPR technology, which provide research support and funds to pursue its pipeline development. It is also developing EDIT-301 for sickle cell disease and beta-thalassemia. However, due to lack of a marketed product, Editas is heavily dependent on its partners for collaboration revenues, which remains a concern. Shares have outperformed the industry in the past year." (1/14/2020) 2. Chardan Capital analysts commented, "We anticipate better visibility around potential timing of data readouts as dosing gets underway. Below, we highlight thoughts on what we know of the program thus far." (7/25/2019) Has Editas Medicine been receiving favorable news coverage? Media stories about EDIT stock have trended extremely negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Editas Medicine earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Editas Medicine. Who are some of Editas Medicine's key competitors? Some companies that are related to Editas Medicine include argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD) and Denali Therapeutics (DNLI). What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP), Advanced Micro Devices (AMD), Canopy Growth (CGC), TransEnterix (TRXC) and Baidu (BIDU). Who are Editas Medicine's key executives? Editas Medicine's management team includes the folowing people: Dr. Charles Albright, Chief Scientific Officer (Age 61)Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)Dr. Feng Zhang, Co-Founder & Scientific Advisory Board MemberDr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member When did Editas Medicine IPO? (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Global Thematic Partners LLC (0.82%), AE Wealth Management LLC (0.05%), Assenagon Asset Management S.A. (0.05%), Focused Wealth Management Inc (0.03%), Patriot Financial Group Insurance Agency LLC (0.01%) and Farmers & Merchants Trust Co of Chambersburg PA (0.01%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine. Which major investors are selling Editas Medicine stock? EDIT stock was sold by a variety of institutional investors in the last quarter, including Focused Wealth Management Inc. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Cynthia Collins and Vickesh Myer. View Insider Buying and Selling for Editas Medicine. Which major investors are buying Editas Medicine stock? EDIT stock was purchased by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Assenagon Asset Management S.A., AE Wealth Management LLC, Farmers & Merchants Trust Co of Chambersburg PA, Patriot Financial Group Insurance Agency LLC, Exchange Traded Concepts LLC, Endurance Wealth Management Inc. and Valeo Financial Advisors LLC. View Insider Buying and Selling for Editas Medicine. How do I buy shares of Editas Medicine? Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $28.35. How big of a company is Editas Medicine? Editas Medicine has a market capitalization of $1.45 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.View Additional Information About Editas Medicine. What is Editas Medicine's official website? The official website for Editas Medicine is http://www.editasmedicine.com/. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected] MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 249 (Vote Outperform)Underperform Votes: 338 (Vote Underperform)Total Votes: 587MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: How prevalent are 12b-1 fees?
